MacTel cases typically present at 40-60 years of age with abnormal right-angled juxtafoveolar capillaries and parafoveal telangiectasias. MacTel is an uncommon disease with a 0.0045-0.1% population prevalence and no obvious sex bias [1] [2] [3] . Retinal lesions typically copresent with MacTel, including retinal transparency, outer retinal and choroidal neovascularization, lamellar holes or foveal cysts, photoreceptor dysfunction, minimal exudation, yellow-white parafoveal crystals, and retinal pigment epithelium (RPE) pigmentation abnormalities and atrophy. Central vision impairment and decreased visual acuity are the usual clinical outcomes. MacTel is a bilateral disease, but asymmetry of the eyes for disease severity and presence of lesions is possible. The lesions also occur in 0.06-1.18% of the general population 2 .
substructure (without PC1, genomic λ = 1.141; with PC1, genomic λ = 1.035). Additional principal components increased the genomic inflation factor with no difference to the key results, likely owing to the small sample size.
SNPs at six loci surpassed the genome-wide significance threshold (P < 5 × 10 −8 ; Fig. 1 and Supplementary Tables 2 and 3) . Three of these loci (at 1p36.22, 3p24.1 and 7p21.3) were discounted as false positives after failing technical validation steps (Online Methods). The remaining three loci (at 5q14.3, 2q34 and 1p12) included 149 SNPs that reached genome-wide significance (Fig. 2) . Seven of the 149 SNPs ( Table 2) were genotyped in an independent, ancestrally European cohort of 172 MacTel cases and 1,134 controls. Selection of SNPs for replication was governed by the ability to create TaqMan assays. We ensured that at least one genotyped, rather than imputed, SNP was selected at each locus. As it was not possible to perform PCA on the replication cohort, the replication analysis was performed without covariates. SNPs at all three loci replicated association (P < 0.01; Table 2 ).
Locus 5q14.3
At 5q14.3, 116 SNPs were genome-wide significant within a 400-kb region, including the strongest associated variant in our study, rs73171800 (per-allele OR = 2.41, 95% confidence interval (CI) = 1.96-2.96; P = 7.74 × 10 −17 ). Two SNPs were selected for replication at this locus, rs17478824 and rs73173548, and both associated with MacTel in our independent cohort ( Table 2) . Among the other genome-wide significant SNPs at this locus were rs2194025 (per-allele OR = 2.31, 95% CI = 1.88-2.84; P = 1.97 × 10 −15 ) and rs17421627 (per-allele OR = 2.43, 95% CI = 1.93-3.06; P = 3.51 × 10 −14 ). All five of these variants are in strong linkage disequilibrium (LD; pairwise r 2 = 0.73-0.98), and their minor alleles confer risk to MacTel. Similarly, the minor alleles of both rs2194025 and rs17421627 have been associated with increased retinal venular and arterial calibers ( Table 3) 15, 16 . A broader region encompassing this 5q14.3 locus is implicated in capillary malformation (MIM 163000) and hereditary benign telangiectasia (MIM 187260), two cutaneous vasculature abnormality traits that may be variable expressions of the same disorder with possible within-family comorbidity [17] [18] [19] . Hereditary benign telangiectasia has been linked to a 7-Mb region at 5q14. 1-14.3 (ref. 17) . Capillary malformations have been linked to a 19-Mb region at 5q14. 1-15 (refs. 18,20) , and germline mutations of the gene RASA1 (encoding RAS p21 protein activator (GTPase-activating protein) 1) were identified as the likely cause for the disorder, albeit with phenotypic variability [21] [22] [23] [24] . Murine knockout models for Rasa1 are embryonic lethal and display vascular abnormalities 25 . A microdeletion at 5q14.3 that includes the genes RASA1 and MEF2C (myocyte enhancer factor 2C) is also implicated in capillary malformations 26 . Our top associated SNP rs73171800 is intergenic at this locus, and the broader associated region is within the bounds of the 5q14.3 microdeletion but does not include RASA1 or MEF2C, which are around 1 Mb proximal and 100 kb distal, respectively. The nearest genes are TMEM161B, TMEM161B-AS1, LINC102546226 and LINC00461, which are largely uncharacterized. The role of RASA1 in angiogenesis and capillary malformations makes it an interesting candidate for MacTel. However, MEF2C is closer to the locus, is endothelially expressed and is involved in early murine vascular development 27 . MEF2C haploinsufficiency causes several neurological disorders, including cortical malformations, epilepsy and mental retardation 28, 29 . Mef2c is involved in murine synaptic development and regulation of synaptic transmissions 30 . Murine Mef2c knockout models are embryonic lethal 31 and display vascular abnormalities 27 , including tissue-dependent lumen size variability and defective vascular remodeling 32 . With respect to the late-onset characteristic of MacTel, initial vasculogenesis in Mef2c-null mice is reported normal, but anomalies arise later on in development, albeit still during embryogenesis 32 . Vascular endothelial growth factor A (VEGFA) 33 , a key player in angiogenesis, controls MEF2C expression in retinal epithelial cells. An antiangiogenic role for MEF2C during stress conditions has been suggested 34 . Epithelial cell-specific Mef2c-null mice suppress retinal vascular degeneration and promote retinal vessel regrowth in response to oxygen-induced retinopathy but not during normal, unstressed retinal vasculature development 34 . Mef2c retinal-specific regulation is controlled by an alternative promoter regulated by the transcription factor neural retina leucine zipper (NRL) 35 . Nrl-null mice lack rod function 36 , and mutations of NRL cause retinitis pigmentosa 27 (MIM 613750) 37 .
Locus 2q34
At 2q34, an 83-kb region contained 21 variants reaching genome-wide significance and included the gene CPS1 (carbamoyl-phosphate synthase 1, mitochondrial). This gene encodes a rate-limiting mitochondrial enzyme that performs the first step of the urea cycle, converting 0  1  2  3  4  5  6  7  8  9  10  11  12  13 14  15 16 17 18  19  20  21  23   5   10   15   20 -log 10 (P)
Chromosome Figure 1 Genome-wide plot of association. SNPs on sequential chromosomes are alternatively colored blue and orange. The x axis represents chromosomal position, and the y axis represents the −log 10 (P value) of association for each SNP with MacTel as tested by logistic regression with PC1 as a predictor to correct for population stratification. Analysis was performed with 476 MacTel cases and 1,733 controls. Red and blue horizontal lines correspond to the thresholds for genome-wide significant and suggestive association, respectively.
ammonia and hydrogen carbonate into carbamoyl phosphate (Fig. 3) . Mutations of CPS1 cause carbamoylphosphate synthetase I deficiency (MIM 237300) and may lead to death by hyperammonemia 38 . Our most significant SNP at this locus, rs715 (per-allele OR = 0.50, 95% CI = 0.42-0.60; P = 9.972 × 10 −14 ), resides within the 3′ UTR of CPS1. We replicated associations with rs715 and rs4673553, another genomewide significant SNP at this locus, in our independent cohort ( Table 2) . We found that the major allele of rs715 confers risk for MacTel. Other GWAS have associated rs715 with several blood metabolite levels [39] [40] [41] [42] : in particular, the major allele was associated with decreased glycine 39, 40, [42] [43] [44] and serine 42 ( Table 3) . Our estimates for the rs715 effect sizes for MacTel are comparable to those for glycine levels 42, 43 ( Supplementary Fig. 6 ). Another SNP at this locus, rs2216405, has also been associated with blood plasma glycine levels 45, 46 and metabolic ratios involving glycine 47 , and it approached genome-wide significance in our study (per-allele OR = 0.54, 95% CI = 0.43-0.68; P = 9.426 × 10 −8 ). These three SNPs are in moderate LD (pairwise r 2 = 0.27-0.48). The variant rs1047891 (renamed from rs7422339) causes a threonine-toasparagine missense substitution within CPS1 and has been associated with blood plasma levels of glycine 48, 49 , other metabolites 48, [50] [51] [52] [53] [54] [55] [56] [57] [58] , blood flow 56 and vasodilator response 56 . In our study, rs1047891 was imputed; it was excluded because of a low imputed genotype call rate (93.4%) but otherwise would have been significant with the remaining available data (P = 1.784 × 10 −11 ). There is strong LD between rs715 and rs1047891 (pairwise r 2 = 0.97). Several studies report a marked sex effect for CPS1 associations, with females showing stronger association for rs715 with glycine levels 43, 44 and rs1047891 with homocysteine levels 54, 55 . We also observed a sex interaction with MacTel at this locus (Online Methods and Supplementary Table 4) . We found that females are at nearly two times greater risk of MacTel for each additional copy of the rs715 risk allele (female-specific per-risk-allele OR = 2.58, 95% CI = 2.00-3.36; male-specific per-risk-allele OR = 1.40, 95% CI = 1.08-1.81).
Our estimates for the rs715 sex-specific effect sizes for MacTel are comparable to those for glycine levels 43 ( Supplementary Fig. 6 ).
Locus 1p12
At 1p12, a region of 46.4 kb contained 12 genome-wide significant SNPs. We replicated this signal in our independent cohort with the imputed SNP rs483180 ( Table 2 ). This region includes the genes PHGDH (phosphoglycerate dehydrogenase) and HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2, mitochondrial). GWAS have associated blood plasma serine levels with intronic PHGDH variants 43, 45 , including our most significant discovery-stage SNP at this locus, rs477992 (per-allele OR = 1.70, 95% CI = 1.47-1.97; P = 2.60 × 10 −12 ), and also rs478093 (per-allele OR = 1.67, 95% CI = 1.44-1.94; P = 2.89 × 10 −11 ). Here we found that the minor alleles of rs477992 and rs478093 confer risk for MacTel, and the same alleles are associated with decreased serine levels in other studies ( Table 3 ) 43, 45 . PHGDH encodes a rate-limiting enzyme that performs the first step of the phosphorylated pathway of serine biosynthesis, converting 3-phosphoglycerate into phosphohydroxy pyruvate (Fig. 3) . PHGDH mutations may lead to PHGDH deficiency (MIM 601815), a severe neuropathological disorder with reduced plasma and cerebrospinal fluid serine levels 59 . HMGCS2 encodes mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase (HMG-CoA synthase-2), an enzyme integral to ketogenesis. Mutations of HMGC2 lead to hypoketotic hypoglycemia due to HMG-CoA synthase-2 deficiency 60 .
Suggestive loci
There were 25 loci that showed suggestive evidence for association with MacTel (1 × 10 −5 > P ≥ 5 × 10 −8 ; Supplementary Table 2 ). Given A r T i c l e S were derived from a logistic regression model, using PC1 as a covariate in the discovery stage. d While all meta-analyses shown were performed with random-effects modeling, a difference from fixed-effects modeling was observed with only two SNPs.
our associations with CPS1 and PHGDH, two genes implicated in serine and glycine blood plasma levels, we explored our 25 suggestive loci for overlap with GWAS for these metabolite levels 39, 40, 42, 43, 45 and identified the loci at 3q21.3 and 7p11.2 ( Fig. 4) . At 3q21.3, rs1107366 has been associated with blood plasma glycine to serine ratios and clamp-based insulin sensitivity 43 , and rs10934753 has been associated with homocysteine levels and incident ischemic stroke 58 . Here these two specific SNPs were not associated with MacTel (rs1107366, P = 0.021; rs10934753, P = 0.072); however, two other SNPs at this locus were suggestively associated, rs9820286 (perallele OR = 0.61, 95% CI = 0.49-0.75; P = 5.38 × 10 −6 ) and rs9880406 (per-allele OR = 0.63, 95% CI = 0.52-0.77; P = 8.98 × 10 −6 ). While rs1107366 and rs10934753 are in strong LD (r 2 = 0.86) and so are rs9820286 and rs9880406 (r 2 = 0.88), the LD between these two pairs is very low (r 2 < 0.012), suggesting that they are tagging two separate signals. We were able to replicate the association with MacTel for rs9880406 in our independent replication cohort ( Table 2 ). This locus lies between the genes ALDH1L1 (aldehyde dehydrogenase 1 family, member L1) and KLF15 (Kruppel-like factor 15). ALDH1L1 is a wellcharacterized gene that encodes the cytosolic enzyme 10-formyltetrahydrofolate dehydrogenase, which catalyzes the conversion of 10-formyltetrahydrofolate into tetrahydrofolate and carbon dioxide or formic acid (Fig. 3) 61 . ALDH1L1 is a highly specific antigenic marker of astrocytes 62 , a type of glial cell critical for retinal angiogenesis during development [63] [64] [65] . Transcriptome analysis suggests that astrocytes have an enrichment of metabolic pathways for amino acids such as serine, glycine and cysteine and pathways for the production and processing of glutamate into glutamine for transport to neurons 62 . Mutations of another aldehyde dehydrogenase, ALDH3A2, may cause Sjögren-Larsson syndrome (MIM 270200), a multifaceted neurological disorder with juvenile macular dystrophy 66 . Unlike other maculopathies, MacTel and Sjögren-Larsson syndrome have co-occurring blue light reflectance abnormalities and retinal crystalline deposits. KLF15 encodes a transcription factor that regulates the gene LRP5 (low-density lipoprotein receptor-related protein 5), mutations of which have been associated with the dysplastic retinal vasculature disorder exudative vitreoretinopathy 4 (MIM 603506) 67 .
At 7p11.2, rs4947534 and rs4948102 are associated with blood plasma serine levels 42 and homocysteine levels 58 , respectively. We found suggestive genome-wide significance for both rs4947534 (perallele OR = 1.44, 95% CI = 1.23-1.68; P = 5.38 × 10 −6 ) and rs4948102 (per-allele OR = 1.46, 95% CI = 1.25-1.70; P = 2.25 × 10 −6 ) in our discovery stage. Furthermore, our strongest signal at this locus was for rs4948102. We selected SNPs rs4535700 and rs11238389 for replication testing, and rs4535700 was nominally significant (P < 0.01). The variants rs4947534, rs4948102 and rs11238389 are in perfect LD (r 2 = 1) and are in high LD with rs4535700 (r 2 > 0.94). The minor allele of these SNPs is associated with MacTel risk, and, similarly, the minor allele of rs4947534 is associated with reduced serine levels 42 and increased homocysteine levels 58 (Table 3) . Both rs4947534 and rs4948102 are within the gene PSPH (phosphoserine phosphatase), the protein product of which catalyzes the final step in the synthesis of serine by converting phosphoserine into serine (Fig. 3) . PSPH mutations may cause phosphoserine phosphatase deficiency, a syndrome with multiple clinical features including reduced plasma levels of serine 68 .
These suggestive loci require validation in independent cohorts to confirm association with MacTel.
Prediction modeling
Our final model incorporated the three validated and two suggestive loci with additive effects, PC1 and one interaction term between sex and 2q34 (Online Methods). Additive modeling was applied because univariate logistic regression analysis showed that it had no significant improvement at these five loci when compared to dominant or recessive models (Supplementary Table 5 ). As the inclusion of PC1 made only a nominal improvement to the prediction model in the discovery cohort (Supplementary Table 6 ) and because we could not derive PC1 for the replication cohort, we estimated the probability of MacTel for each sample in the training set (discovery cohort; Supplementary  Figs. 7-9 ) and validation set (replication cohort; area under the curve (AUC) = 0.679; Supplementary Figs. 10-12 
Metabolomics analysis
Blood serum levels of 799 metabolites, including glycine and serine, were compared between 50 MacTel cases and 50 independent controls matched for age, sex, ancestry and diabetes status (Online Methods). Student's t-tests were significant for both glycine (T = −6.98; P = 3.51 × 10 −10 ) and serine (T = −5.39; P = 4.79 × 10 −7 ). Given an observed inflation in our results (Supplementary Fig. 17 ), we applied a correction akin to 'genomic control' with an inflation factor of 1.753 (P glycine = 4.04 × 10 −6 ; P serine = 2.48 × 10 −4 ). Serum levels were lower in the MacTel cases than in the controls (glycine, log 2 (fold change) = −0.541; A r T i c l e S serine, log 2 (fold change) = −0.382). Of all 799 metabolites, glycine and serine were ranked first and third most significant, respectively. Another glycine/serine pathway amino acid, namely threonine, was the second most significant metabolite, thereby reinforcing our glycine and serine results. Sample genotype data were not available.
In silico variant functional exploration
We used the online GTEx Project 69 portal to search for expression quantitative trait locus (eQTL) signatures in the SNPs showing at least suggestive association (P < 1 × 10 −5 ) at each of the three validated and two suggestive loci ( Tables 8 and 9) . The SNPs at 2q34 and 3q21.3 did not yield any cis eQTLs. At 1p12, SNPs with the strongest association to MacTel also showed the strongest association to gene expression levels, with eQTLs observed in two tissues each for both ZNF697 and PHGDH. For PHGDH, the direction of effect was tissue specific.
At 5q14.3, MacTel risk alleles associated with increased expression of TMEM161B-AS1, the antisense RNA to TMEM161B, in nearly every tissue tested. However, the genome-wide significant 5q14.3 MacTel risk SNPs (P < 5 × 10 −8 ) were not driving the majority of these eQTL associations; instead, the eQTLs were driven by the SNPs showing suggestive association with MacTel (1 × 10 −5 > P ≥ 5 × 10 −8 ). This suggests that, while the MacTel risk SNPs are indeed affecting the expression of TMEM161B-AS1, they may be having a stronger unobserved functional effect on TMEM161B-AS1 or other genes.
eQTLs at the suggestive 7p11.2 locus were observed in multiple genes for a limited number of tissues, and the direction of effect was gene specific. Similar to the 1p12 locus, the SNPs with the greatest association to MacTel risk also had the greatest association to gene expression levels.
Methylation and H3K4me3 histone modification architecture around the three significant and two suggestive loci were analyzed in the UCSC Genome Browser (Supplementary Figs. 18-22) . H3K4me3 was selected because of its known association with transcriptional activity. At the 1p12 locus, there is a strong H3K4me3 signature and a moderate unmethylated DNA signature around the strongest associated MacTel SNPs at the start of PHGDH. This supports the eQTL results and suggests that these SNPs may affect expression of PHGDH. At 2q34 and the suggestive 3q21.3 locus, there are no notable H3K4me3 signatures, but a weak methylation signature is evident at 2q34, indicative of gene silencing. At 5q14.3, there is a small but robust H3K4me3 mark at the most strongly associated MacTel risk SNPs downstream of TMEM161B-AS1. Finally, at 7p11.2, the suggestive MacTel risk SNPs do not overlay any H3K4me3 modification or methylation signatures, but they do lie immediately adjacent to such signatures, suggesting that they could be influencing the DNA structure by virtue of their proximity.
Interpretation of these results is difficult given that we do not have any strong a priori expectation of the particular tissues that would be of interest for MacTel and the absence of eye tissue in the GTEx resource.
DISCUSSION
Here we identified three validated and two suggestive genetic loci for MacTel. While these loci include several plausible candidate genes, they account for only ~5% of the estimated heritability, suggesting that more loci await discovery.
We do not find association with any candidate genes we previously screened or any genes within the linkage region we previously reported (here the most significant discovery-stage signal within the linkage region was with rs17352829; P = 9.83 × 10 −5 ) 13, 14 . A rat model for MacTel carrying an insertion-deletion mutation within the gene Crb1 has been described 70 ; however, we find no associated signal at this locus either.
Misdiagnoses can occur between MacTel and age-related macular degeneration (AMD). Hence, we searched for any overlap between our top association signals and those previously reported for AMD [71] [72] [73] Table 2 ). TIMP3 is associated with both AMD and another maculopathy, Sorsby fundus dystrophy (SFD) (MIM 136900), which presents earlier in life than AMD but shares some clinical features 74 . The TIMP3-SYN3 locus has also been suggestively associated with serine and glycine levels (see The Metabolomics GWAS Server 42, 45 ).
A r T i c l e S (Supplementary

Major cell types of the retina include vascular cells, neuronal cells (rods and cones) and glial cells (microglia, Müller glia and astrocytes).
Glial cells envelop the neurons and provide them with a homeostatic environment, supporting their survival and serving as an intermediary with blood vessels 75, 76 . Müller glial cells remove neurotransmitters, including glutamate and glycine, from synaptic spaces to prevent eventual neurotoxicity and enable continued synaptic functioning. Müller cells also detoxify ammonia by expressing the enzyme glutamate-ammonia ligase (glutamine synthetase) 75 79 .
Retinal neurovascular coupling is important for the maintenance of local functionality, homeostasis and regulation of local blood supply 80 . The neurovascular unit that facilitates this function includes neurons, pericytes, endothelial cells and glia. Astrocytes and Müller glia regulate blood flow by vasoconstriction and vasodilation 81 ; hence, aberrant functioning of these cells may affect this regulated control of vascular caliber and, thereby, blood flow 82 . Because we previously reported an association between MacTel and increased retinal vasculature calibers 82 , our findings here linking MacTel risk alleles at 2q34 and 5q14.1 with increased vasodilation and with venular and arterial calibers, respectively (Table 3) , may be relevant.
We found that the MacTel risk alleles at 1p12, 2q34 and suggestive locus 7p11.2 were previously associated with decreased serine levels ( Table 3) , and we find that serine and glycine serum levels are significantly lower in MacTel cases. The serine pathway involves ammonia and glutamate substrates, and it is plausible that a perturbation of this system due to defective enzyme activity might prevent Müller glia from performing their multifaceted functions normally. Altered expression of PHGDH, PSPH, ALDH1L1 or CPS1 (at 1p12, 7p11.2, 3q21.3 and 2q34, respectively) could lead to the observed decreases in serine levels and consequently to hyperammonemia and hyperglutamate conditions of a neurotoxic level, thereby causing retinal stress and damage. Müller glia and other cells react to retinal damage and stress by undergoing gliosis, a process that includes expression changes in glutamate-ammonia ligase and the induction of VEGFA expression. MEF2C (at 5q14.3, the strongest genome-wide associated locus) is under the control of VEGFA and may normally prevent stress-induced angiogenesis. Hence a defective variant of MEF2C may be unable to suppress angiogenesis during retinal damage.
Müller glia also remove neuron-derived carbon dioxide by expressing carbonic anhydrases (CAs) 75, 76 that catalyze the reaction of carbon dioxide and water into hydrogen carbonate. One of the few drugs reported thus far with a positive effect on MacTel is acetazolamide, which reduces cystic lesions 83 . Acetazolamide is a CA inhibitor (Fig. 3) . The hydrogen carbonate produced by Müller cells may be released into the vitreous body or bloodstream 76 . CPS1 uses hydrogen carbonate and ammonia as substrates for the urea cycle (chiefly in the liver).
Previously, we showed that glycolytic pathway genes have reduced expression in the MacTel macula in comparison to either non-macula retinal tissue of the same eye or healthy macula tissue 78 and a reduction in expression of glycolytic pathway genes following Müller cell ablation 79 . The former study observed a difference in expression of the enzyme phosphoglycerate kinase whose substrate is 3-phosphoglycerate. We find an association with PHGDH, which encodes an enzyme whose substrate is also 3-phosphoglycerate (Fig. 3) , suggesting that both the glycolytic and serine pathways may be perturbed by PHGDH in the etiology of MacTel. . For each plot, the x axis is scaled such that 100 kb flanks each end of the locus as defined by the first and last SNPs reaching suggestive significance (P < 1 × 10 −5 ), and the y axis represents the −log 10 (P value) of association for each SNP. Individual SNPs are represented as colored circles (genotyped) or crosses (imputed). For b, the sole purple cross represents the most significantly associated SNP at that locus in the discovery stage, and the other markers are colored according to their LD with that SNP; however, for a, the coloring is with respect to rs9880406 (the sole purple circle). Recombination rates and LD were estimated from the EUR 1000 Genomes Project March 2012 release, build hg19.
A r T i c l e S
Despite MacTel and diabetes being associated (as reflected in our sample ascertainment; Table 1), our study finds very limited sharing of genetic risk at the three significant and two suggestive loci for the two disorders. Only the suggestive 3q21.3 locus has shown marginal association with clamp-based insulin sensitivity, whereas the other four loci have not been associated with any diabetesrelated traits (Table 3) .
Here we identified three validated and two suggestive loci with the maximal observed odds ratio at each locus ranging from 1.43 to 2.46 for each additional risk allele. Risk factors of similar, and smaller, effect size have been discovered using GWAS for AMD 72 . Further risk factors for MacTel will likely be identified using additional cohorts.
We report the first GWAS for MacTel and find genetic and metabolomic results implicating the glycine/serine metabolic pathway. We recognize that glycine and serine may not be the actual driver metabolites for MacTel. However, they may still be useful biomarkers for prediagnostic screening in at-risk individuals, and our findings may lead to metabolite or enzymatic supplementation as a course for prevention or slowing disease progression. Further studies are needed to validate these associations and to determine whether targeting those metabolites could become a useful strategy for screening or treatment. We also link MacTel with the glycolytic pathway and confirm a reported link between MacTel and retinal venular caliber, thereby increasing understanding of the disease. 
URLs
METhODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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exclude individuals with cataracts, retinitis pigmentosa, color blindness, other congenital eye problems, LASIK, artificial lenses, and other eye surgery."
Replication-stage control samples were of European ancestry and came from the Electronic Medical Records and Genomics (eMERGE) Cincinnati Children's Hospital Medical Center (CCHMC; N subtotal = 505) study and Columbia University (N subtotal = 629). The CCHMC controls were diagnosed with eosinophilic esophagitis, had an age range of 2-52 years and had Illumina Omni5 SNP chip data available from dbGaP (project "Better Outcomes for Children: GWAS from Cincinnati Children's Hospital Medical Center (CCHMC)-eMERGE Phase II data"; phs000494.v1.p1) (ref. 88) . The Columbia University controls were confirmed as being of European ancestry by questionnaire during recruitment, have been used as controls for studies of AMD as described previously 72, 89, 90 , were of an advanced age (mean age 74.8 ± 7.1 years), did not exhibit any distinguishing signs of macular or retinal disease after clinical examination by trained ophthalmologists and had no known family history of retinal disease.
DNA sample preparation and quality control. For MacTel Project consortium samples and Columbia University control samples, DNA was extracted from peripheral venous blood (Qiagen Blood maxi kit, 51194). DNA concentration was determined with the Qubit Fluorometer (Thermo Fisher Scientific). DNA samples of low purity were subjected to column purification (Qiagen Blood and Tissue kit, 69504).
GWAS genotyping and quality control. The GWAS discovery stage used a final quality-controlled data set of 2,209 samples (N cases = 476; N controls = 1,733; Table 1 ).
AREDS genotypes were obtained from NCBI's dbGaP record (project "NEI Age-Related Eye Disease Study (AREDS)-Genetic Variation in Refractive Error Substudy"; phs000429, substudy of phs000001). AREDS samples were genotyped with Illumina Omni2.5 SNP chips. Genotypes for 2,182,680 variants/probes for 1,657 samples were downloaded from dbGaP, and those with minor allele frequencies (MAFs) <1%, or else monomorphic, were removed. Complementary biallelic (AT or CG) SNPs were removed because of strand uncertainty; these would otherwise cause problems when merging with the MacTel Project genotypes. For SNPs with identical chromosome identifiers and base-pair positions, only the one with the least missingness was kept. Identity-by-descent (IBD) sharing was assessed using PLINK1. 9 (refs. 91,92) , and a kinship coefficient threshold of 0.04 was determined to establish independence of samples. Further filtering took place as described below in conjunction with the MacTel Project samples.
From our MacTel Project cohort, a total of 704 samples (including MacTel cases and controls) were genotyped with the Illumina Omni5 SNP chip for the discovery stage. Illumina GenomeStudio software with default genotyping settings produced genotypes for a total of 4,641,218 variants/probes. DNA samples with genotype call rate <95% or unexpected or unusual sex-chromosome call rates were flagged and removed. Monomorphic probes or variants with MAF <1% were filtered out. Complementary biallelic (AT or CG) SNPs were removed because of strand uncertainty. For SNPs with identical chromosome identifiers and base-pair positions, only the one with the least missingness was kept. Sample independence was tested by assessing IBD sharing using PLINK1. 9 (refs. 91,92) and applying a kinship coefficient threshold of 0.04. When IBD analysis suggested relatedness, a single sample was selected, which was usually the sample with the least missingness.
AREDS and MacTel project SNP genotypes were merged, and differential missingness was assessed between the two cohorts by Fisher's exact tests and an exclusion threshold of P < 0.001. A mock GWAS was performed on the 76 MacTel Project consortium controls against the 1,657 AREDS controls. A quantile-quantile plot of this analysis shows little deviation between the expected and observed P values (Supplementary Fig. 23 ). Further IBD analysis was performed to ensure no relatedness between AREDS and MacTel project samples. PCA of the samples was performed with EIGENSOFT and PLINK to identify any population substructure (Supplementary Figs. 2-4) . This was achieved using 29,149 independent genome-wide SNPs selected with PLINK using the "--indep-pairwise" option; this assessed pairwise Pearson's correlations (r) within windows of 1,000 adjacent SNPs and greedily pruned these SNPs until no such pairs remained with r 2 >0.04, before sliding the window a further 50 bp along.
Imputation Before statistical analysis, a final round of filtering removed any SNPs with >5% genotype missingness, Hardy-Weinberg equilibrium exact test P < 1 × 10 −6 or MAF <5%.
GWAS statistical analysis.
For the discovery stage, 2,209 samples (476 MacTel cases and 1,733 controls) with genotypes for 6,310,381 SNPs were analyzed by logistic regression with PLINK1. 9 (ref. 92) . PC1 from the PCA was added to the logistic regression model as a covariate in the discovery stage. The scree plot indicated that additional principal components would have a negligible contribution (Supplementary Fig. 3 ). Quantile-quantile plots ( Supplementary  Fig. 5 ) and Manhattan plots ( Fig. 1 and Supplementary Fig. 24 ) were created in R with the qqman package 96 . The top associated loci (P < 1 × 10 −5 ) are summarized in Supplementary Tables 2 and 3 . Local association plots (Figs. 2 and 4) were constructed with LocusZoom 97 . The top SNP at each locus was also tested in PLINK using logistic regression with dominant and recessive modeling of the minor allele (A1) (Supplementary Table 5 ).
GWAS power calculations.
We maximized the power of our GWAS discovery stage by using all MacTel Project cases available at the time. For GWAS of diseases such as MacTel, which are studied for the first time, it is not known what the expected effect size is. Power calculations were therefore performed post hoc with the Genetic Power Calculator 98 , assuming a population prevalence of 0.001, D′ = 1 (between the risk marker and true causal marker), α = 5 × 10 −8 (significance level), a range of genotypic relative risks and allele frequencies and using the allelic test (Supplementary Fig. 1 ). Given 476 cases and 1,733 controls, genotypic relative risks of 2 for genotype Aa and 4 for genotype AA, relative to the baseline genotype aa, and risk allele frequencies ranging from 0.20 to 0.60, would have >0.99 power. However, genotypic relative risks of 1.5 and 2.25 for the genotypes Aa and AA would only have a peak power of 0.53 with a risk allele frequency of ~0.4, thus demonstrating the limit of our GWAS discovery stage.
Replication analysis. The six loci that reached genome-wide significance were selected for replication (Fig. 2, Supplementary Figs. 25-27 and Supplementary Table 2 ). Three of these loci were subsequently ruled as false positives after attempts to technically validate them on an independent genotyping platform (TaqMan assays, Applied Biosystems) yielded uncorrelated genotypes (a low concordance rate). We identified two further loci on chromosomes 3 and 7 that showed suggestive evidence for association and warranted replication. This was based on their reported association with the serine and glycine metabolic pathways in other independent studies. Genotyping of the SNPs for replication at these five loci (three genome-wide significant and two suggestively associated) was performed by TaqMan assay in the new MacTel cases and Columbia University controls (Supplementary Fig. 28 ). Assays were purchased from Applied Biosystems as validated, inventoried SNP assayson-demand or were submitted to the Applied Biosystems Assays-by-Design pipeline. The choice of these SNPs for replication was limited by the ability to create TaqMan assays. Furthermore, we ensured that at least one actual genotyped, rather than imputed, SNP was selected at each locus. The genotyping technique used was identical to that described previously 90 . Briefly, 5-10 ng of DNA was subjected to 50 cycles on an ABI 9700 384-well thermocycler, and plates were read on an Applied Biosystems 7900 HT Sequence Detection System. CCHMC control genotypes were generated with the Illumina Omni5 platform (data were unavailable for rs483180 and rs11238389).
Analysis in the replication cohort was performed with PLINK using a logistic regression framework and no covariates.
Power calculations were performed for the replication analysis. Given a replication cohort of 172 cases and 1,134 controls, a population prevalence of 0.001, α = 0.01, D′ = 1 (between the risk marker and true causal marker), and the odds ratios and allele frequencies of the top SNP at each locus, we estimated >97% power to replicate the top three genome-wide significant loci with the allelic test. At the two suggestively significant associated loci, 3q21.3 and 7p11.2, the power was 0.5943 and 0.7033, respectively. Meta-analysis. Given the differences in ascertainment of the controls used for the discovery and replication stages and that a covariate was applied to the discovery-stage analysis but not to the replication stage, meta-analyses between the discovery and replication stages for the top hits were performed with a random-effects model in PLINK as previously described 99 (Table 2) . Only two of the ten SNPs tested showed signs of differing effect sizes between the discovery and replication cohorts, while the results for the other eight SNPs were identical to modeling by fixed effects.
Heritability estimates. Heritability on the liability scale was estimated using a linear mixed model method, developed by Yang et al. 100 and adapted for dichotomous traits by Lee et al. 101 , applied to the 1,093,805 directly genotyped SNPs from the discovery stage (no imputed SNPs). Applying a population prevalence of 0.0045% and 0.1% yielded h 2 of 0.21 and 0.74, respectively, with 5% of this h 2 explained by the three replicated and two suggestive loci (for both prevalence rates).
Prediction modeling. Logistic regression prediction modeling was performed in R with the GWAS discovery-stage cohort, using the strongest associated SNP that replicated at each of the five loci as predictors and with PC1 and sex as covariates (Supplementary Table 6 ). Initially, a variable selection procedure investigated the relevance of the interaction terms between sex and the SNPs and any epistatic effects. Once a stable model was selected, its predictive power was assessed. The genotypic effect for all markers was modeled as additive to be consistent with the discovery stage. We have shown that the additive model best describes the loci on chromosomes 1, 2, 5 and 7, and there is a marginal difference for the chromosome 3 loci between the additive and recessive models (Supplementary Table 5) . To account for possible population stratification, we included PC1 using orthogonal polynomials of degree three (PC1_1, PC1_2 and PC1_3). Starting with the 'full' model, the variable selection step was performed using backward stepwise regression until convergence was achieved, as measured by the Bayesian information criterion (BIC). Fivefold crossvalidation (CV) was used to perform variable selection with random subsets of the initial data, initialized multiple times with 100 different seeds. Blinding was used for case and control status for performance testing of the prediction model via an automated procedure in R. In total, 11 different models were observed from all 500 fitted models. One model predominated, being selected ~66% of the time, that included the main effects for all five SNPs (three significant and two suggestive), PC1 and the interaction term between sex and the SNP on chromosome 2 (column 4 in Supplementary Table 6 ). We did not observe any significant epistatic effect between SNPs. Using the R package ROCR 102 , a ROC curve was plotted for this model with an AUC of 0.719 (and without PC1 an AUC of 0.707; Supplementary Fig. 13) .
As PC1 was unavailable in the replication cohort (because of the lack of genotype data), this prediction model was applied to our replication cohort for validation after assessing the estimated effects of each SNP in the discovery cohort without PC1. We achieved an AUC of 0.679, thereby validating our results from the discovery cohort (Supplementary Fig. 14) .
Sex-specific odds ratios at 2q34. At 2q34, we derived sex-specific odds ratios for the top most associated SNP (rs715) by performing logistic regression in R with orthogonal polynomials of degree three for PC1 (Supplementary Table 4 ). Considering the risk allele (which is the major allele), we found a borderline significant effect size in males (per-allele OR = 1.40, 95% CI = 1.08-1.81) and a significant association in females (per-allele OR = 2.58, 95% CI = 2.00-3.36).
Metabolomics analysis. Serum was collected from 50 MacTel cases and 50 controls from the wider MacTel Project cohort. Samples were well matched with regard to sex (25 females and 25 males in both cases and controls), age (average of 64 years in the MacTel cases and 63 years in the controls), diabetic status (38 non-diabetics and 12 type 2 diabetics in both cases and controls) and ancestry (48 Caucasian MacTel cases and 47 Caucasian controls).
All individuals fasted overnight, and blood was taken before noon. Around 5 ml of blood was collected in a clot-activating vacutainer tube (Vacutainer Plastic SST II Advance Tube with Gold Hemogard Closure, Becton Dickinson), left at room temperature for 30 min and then centrifuged for 5 min at 1,200g. The supernatant was collected, frozen and stored at −80 °C. Levels of 1,281 metabolites in the serum were measured by Metabolon. Briefly, this involved initial protein precipitation with methanol under vigorous shaking for 2 min (Glen Mills GenoGrinder 2000) followed by centrifugation. The resulting extract was analyzed by reverse-phase ultrahigh-performance liquid chromatography followed by tandem mass spectrometry (UPLC-MS/MS) with positive-ion-mode electrospray ionization (ESI). Peaks were quantified using the AUC technique. Quality control steps were applied to the 1,281 log 2 -transformed metabolite levels, thereby removing 403 for high missingness (>10% missing data for either MacTel cases or controls), 30 for high correlation (|Pearson's r| ≥ 0.95) between any pair of metabolites and 49 with abnormal distributions, thereby leaving a total of 799 metabolites for analysis. Missing metabolite data were then imputed with the minimum value for each metabolite across all samples. Quantile normalization of the data was performed using the R package limma 103 . Metabolite levels were then compared between the MacTel cases and controls by Student's t-test. eQTL analysis. The 419 variants showing at least suggestive association (P < 1 × 10 −5 ) with MacTel at the five loci were tested for association with cis gene expression levels in at least 40 tissues from 572 donors. Here cis is defined as being within ±1 Mb of the transcription start site of each gene. GTEx returns eQTL association results that are beyond specific gene-and tissue-derived significance thresholds.
Data availability. The MacTel consortium genotypes for 678 samples (with consent) of the 704 samples genotyped as part of the discovery stage and that support the findings of this study have been deposited in the European Genome-phenome Archive (EGA), which is hosted by the European Bioinformatics Institute and the CRG, under accession EGAS00001002249.
